In Vivo Efficacy and Pharmacokinetics of AC98-6446, a Novel Cyclic Glycopeptide, in Experimental Infection Models
Open Access
- 1 May 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (5) , 1708-1712
- https://doi.org/10.1128/aac.48.5.1708-1712.2004
Abstract
AC98-6446 is a novel semisynthetic derivative of a natural product related to the mannopeptimycins produced byStreptomyces hygroscopicus. Naturally occurring esterified mannopeptimycins exhibited excellent in vitro activity but only moderate in vivo efficacy against staphylococcal infection. The in vivo efficacy and pharmacokinetics of AC98-6446 were investigated in murine acute lethal, bacterial thigh and rat endocarditis infections. Pharmacokinetics were performed in mice, rats, monkeys, and dogs. Acute lethal infections were performed with several gram-positive isolates:Staphylococcus aureus(methicillin-susceptible and methicillin-resistant staphylococci), vancomycin-resistantEnterococcus faecalis, and penicillin-susceptible and -resistantStreptococcus pneumoniae. The 50% effective dose for all isolates tested ranged from 0.05 to 0.39 mg/kg of body weight after intravenous (i.v.) administration. Vancomycin was more than fivefold less efficacious against all of these same infections. Results of the thigh infection withS. aureusshowed a static dose for AC98-6446 of 0.4 mg/kg by i.v. administration. Reduction of counts in the thigh of >2 log10CFU were achieved with doses of 1 mg/kg. i.v. administration of 3 mg/kg twice a day for 3 days resulted in a >3 log10reduction in bacterial counts of vancomycin-susceptible and -resistantE. faecalisin a rat endocarditis model. Pharmacokinetics of AC98-6446 showed an increase in exposure (area under the concentration-time curve) from mouse to dog species. The i.v. half-life (t1/2) increased threefold between rodents and the higher species dosed. Efficacy of AC98-6446 has been demonstrated in several models of infection with resistant gram-positive pathogens. This glycopeptide exhibited bactericidal activity in these models, resulting in efficacy at low doses with reduction in bacterial load.Keywords
This publication has 30 references indexed in Scilit:
- Linezolid-Resistant, Vancomycin-Resistant Enterococcus faecium Infection in Patients without Prior Exposure to LinezolidClinical Infectious Diseases, 2003
- Staphylococcus aureus Carrier State Among Elderly Residents of a Long–Term Care FacilityJournal of the American Medical Directors Association, 2003
- The Changing Epidemiology of Vancomycin-Resistant EnterococciInfection Control & Hospital Epidemiology, 2003
- Natural History of Colonization With Vancomycin-Resistant Enterococci, Methicillin-Resistant Staphylococcus Aureus, And Resistant Gram-Negative Bacilli Among Long-Term–Care Facility ResidentsInfection Control & Hospital Epidemiology, 2003
- Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S . aureus under the Impact of Antibiotics Administered for ChemotherapyJournal of Clinical Microbiology, 2003
- Mannopeptimycins, New Cyclic Glycopeptide Antibiotics Produced by Streptomyces hygroscopicus LL-AC98: Antibacterial and Mechanistic ActivitiesAntimicrobial Agents and Chemotherapy, 2003
- Mannopeptimycins, Novel Antibacterial Glycopeptides from Streptomyces hygroscopicus, LL-AC98Journal of the American Chemical Society, 2002
- Surveillance and Control of Methicillin-ResistantStaphylococcus aureusInfections in French HospitalsInfection Control & Hospital Epidemiology, 2001
- Epidemiology and Susceptibility of 3,051 Staphylococcus aureus Isolates from 25 University Hospitals Participating in the European SENTRY StudyJournal of Clinical Microbiology, 2001
- Emergence of Methicillin-Resistant Staphylococcus aureus with Intermediate Glycopeptide ResistanceDrugs, 2001